Compare Gilead Sciences, Inc. (GILD) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lockheed Martin Corporation — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Lockheed Martin Corporation trades at $507.89 (market cap $115.22B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Lockheed Martin Corporation pays the higher dividend (2.76%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Lockheed Martin Corporation for 86 Days on average.
| GILD | LMT | |
|---|---|---|
Market Cap | $182.09B | $115.22B |
Volume | 4,960,247 | 1,073,075 |
Sector | Health | Industrials |
52-Week High | $155.80 | $676.70 |
52-Week Low | $116.74 | $439.19 |
Typical Hold Time | 111 Days | 86 Days |
Enterprise Value | $205.15B | $131.96B |
Dividend Yield | 2.23% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Lockheed Martin (LMT) trades at $507.89, down 0.44% on the day, with a bearish technical signal driven by moving averages. The stock shows strong profitability with an 8.16% net margin and 89.16% ROE, but recent earnings missed expectations in two of the last three quarters. Revenue growth is steady, projected to reach $77B in 2026, while analyst sentiment remains positive with a $645.50 consensus price target. Recent news highlights dividend increases and AI integration initiatives.
The outlook for LMT is supported by robust defense spending and a high analyst buy rating (59%), but risks include fixed-price contract volatility and debt levels. The stock offers a dividend yield near 0.7% with 23 consecutive years of increases. Upside potential exists if earnings rebound, though technical resistance near $510 may cap near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
